anti-CD19 CAR-T cells (The Children's Hospital of Zhejiang University School of Medicine)

This investigational anti-CD19 CAR-T cell therapy is being developed by The Children's Hospital of Zhejiang University School of Medicine for the treatment of multi-drug resistant steroid-resistant nephrotic syndrome (MDR-SRNS). The therapy involves the genetic modification of a patient's own T cells to express a chimeric antigen receptor (CAR) targeting CD19, a protein found on the surface of B cells. By eliminating CD19-positive B cells, the therapy aims to disrupt the B-cell-mediated pathogenic processes underlying nephrotic syndrome. It is currently being evaluated in a Phase 1 dose-escalation study to assess safety and efficacy in pediatric patients who have failed conventional treatments.

Other names

anti-CD19 CAR-T cellsanti-CD-19 CAR-T cellsanti-CD 19 CAR-T cellsanti-CD19 chimeric antigen receptor T lymphocytesanti-CD-19 chimeric antigen receptor T lymphocytesanti-CD 19 chimeric antigen receptor T lymphocytes